Jan 28, 2025 · It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

2 days ago · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD).. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial ...

Jan 28, 2025 · Today, the FDA has expanded the benefits of Ozempic to a new patient population that needs critical treatment options to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

3 days ago · FDA approves Ozempic ® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. News ...

Jan 28, 2025 · The F.D.A. based its decision to expand the approved uses of Ozempic on research showing that people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower ...

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.

Jan 30, 2025 · The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease. This approval makes Ozempic the first GLP-1 treatment for patients with both conditions.

Mar 8, 2024 · The latest green light from the U.S. regulatory agency is based on results from Novo Nordisk’s FLOW trial, which demonstrated that those with type 2 diabetes and chronic kidney disease who took Ozempic (semaglutide) slowed the progression of their kidney disease and cut their risk of death from kidney disease and major cardiac events by 24% ...

May 24, 2024 · Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic...

Jan. 29, 2025 -- The FDA has approved Novo Nordisk's diabetes drug Ozempic to help reduce the risk of worsening kidney disease, kidney failure, and heart-related death in adults with type 2...